Latest Information Update: 10 Jan 1995
At a glance
- Originator Aventis
- Class Radiosensitisers
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 10 Jan 1995 No-Development-Reported for Cancer in USA (Unknown route)